Metabolically controlled reperfusion in acute myocardial infarction: Should the polarizing solution be given subselectively?

Journal of Invasive Cardiology

Volumn 15, Issue 9, 2003, Pages 491-496

  Angelini, Paolo ^a,c   Haas, P Clay ^a   Ducci, Chiara Bucciarelli ^b   Adams, Steven ^a   Ober, Judy ^b   Bigley, Joyce ^b   Clubb, Fred J ^b   Frazier, O H ^b  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b TEXAS HEART INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Acute myocardial infarction; Canine studies; Coronary ischemia; Reperfusion

Indexed keywords

GLUCOSE; INSULIN; OSMOTIC AGENT; POLARIZING AGENT; POTASSIUM; PROPIONYLCARNITINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY LIGATION; CRYSTALLOID; DEATH; DOG; DRUG INFUSION; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART VENTRICLE FIBRILLATION; HEART VENTRICULOGRAPHY; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; POLARIZATION; SAFETY; TREATMENT OUTCOME;

ANIMALS; DOGS; FEASIBILITY STUDIES; FEMALE; MALE; MODELS, ANIMAL; MODELS, CARDIOVASCULAR; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; RECOVERY OF FUNCTION; SOLUTIONS;

EID: 0141701940     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Opie LH. Proof that glucose-insulin-potassium provides metabolic protection of ischemic myocardium? Lancet 1999;353:768-769.
2. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
3. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
4. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21:537-545.
5. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 1994;343:155-158.
6. Taegtmeyer H, Goodwin GW, Doenst T, Frazier OH. Substrate metabolism as a determinant for post-ischemic functional recovery of the heart. Am J Cardiol 1997;80:3A-10A.
7. Taegtmeyer H, Villalobos DH. Metabolic support for the post-ischemic heart. Lancet 1995;354:1552-1555.
8. Sodi-Pallares D, Testelli MR, Fishleder BC, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 1962;9:166-167.
9. Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium: Effect on contractile function, diastolic compliance, metabolism and ultrastructure during ischemia and reperfusion. Circ Res 1983;52:515-526.
10. Maroko PR, Libby P, Sobel BE, et al. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation 1972;45:1160-1175.
11. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation 1997;96:1152-1156.
12. Díaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 1998;98:2227-2234.
13. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction. The time has come for a large, prospective trial. Circulation 1997;96:1074-1077.
14. Fishbein MC, Meerbaum S, Rit T, et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;32:143-147.
15. Gibbons RJ, Christian TF, Hopfenspirger M, et al. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: Implications for the design of randomized trials of acute intervention. J Am Coll Cardiol 1994;24:616-623.
16. Lavallee M, Cox D, Patrick TA, Vatner SF. Salvage of myocardial function by coronary artery reperfusion 1, 2, and 3 hours after occlusion in conscious dogs. Circ Res 1983;53:235-247.
17. Bush LR, Buja LM, Samowitz W, et al. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs: comparison of 2- and 4-hour occlusions. Circ Res 1983;53:248-263.
18. Reimer KA, Lowe JE, Rausmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell-death. 1. Myocardial infarct size versus duration of coronary occlusion in dogs. Circulation 1977;56:786.
19. Ellis SG, Henschke CI, Sandor T, et al. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol 1983;1:1047-1055.
20. Buckberg GD. Studies of controlled reperfusion after ischemia. I. When is cardiac muscle damaged irreversibly? J Thorac Cardiovasc Surg 1986;92:483-487.
21. Opie LH. Pathophysiology and biochemistry of ischemia, necrosis, and reperfusion. In: Gersh BJ, Rahimtoola SH (eds). Acute Myocardial Infarction, 2nd Edition. New York: Lippincott Williams & Wilkins, 1997: pp. 51-68.
22. Taegtmeyer H, Roberts AFC. Energy metabolism in reperfused rat heart: return of function before normalization of ATP content. J Am Coll Cardiol 1985;6:864-870.
23. Broderick TL, Quinney A, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993;87:972-981.
24. Arsenian MA, New PS, Cafasso CM. Safety, tolerability and efficacy of glucoseinsulin-potassium-magnesium-carnitine solution in acute myocardial infarction. Am J Cardiol 1996;78:476-479.
25. Jennings RB, Reimer KA, Steenbergen C. Myocardial ischemia revisited: the osmolar load, membrane damage, and reperfusion. J Mol Cell Cardiol 1986;18:769-780.
26. Spears JR, Henney C, Prcevski P, et al. Aqueous oxygen hyperbaric reperfusion in a porcine model of myocardial infarction. J Invas Cardiol 2002;14:160-166.
27. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998;31:259-264.
28. Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998;31:259-264.
29. Bolli R, Patel B. Factors that determine die occurrence of reperfusion arrhythmias. Am Heart J 1988;115:20-29.
30. Hale SL, Lange R, Alker KJ, Kloner RA. Correlates of reperfusion ventricular fibrillation in dogs. Am J Cardiol 1984;53:1397-1400.
31. Russell RR, Mommessin JI, Taegtmeyer H. Propionyl-L-carnitine-mediated improvement in contractile function of rat hearts oxidizing acetoacetate. Heart Circ Physiol 1995;37:H441-H447.
32. Taegtmeyer H. Fuels of the heart. In: Willerson JT, Cohn JN (eds.) Cardivascular Medicine, 2nd edition. Philadelphia: Churchill Livingstone, 2000: pp. 936-954.
33. Kloner RA, Bolli R, Marban E, et al. Medical and cellular implications of stunning, hibernation and preconditioning. An NHLBI workshop. Circulation 1998;97:1848-1867.
34. Hearse DG. Stunning: A radical review. In: Opie LH (ed.) Stunning, Hibernation and Calcium in Myocardial Ischemia and Reperfusion. Boston: Kluwer Academic Press, 1992: pp. 10-55.
35. Lazar HL. The insulin cardioplegia trial. J Thorac Cardiovasc Surg 2002;123:842-844.
36. Gerritsen ME. Physiologic functions of normal endothelial cells. In: Loscalzo J, Creager MA, Dzau VJ (eds.) Vascular Medicine: A Textbook of Vascular Biology and Diseases. Boston: Little Brown & Co, 1996: pp. 1-25.